Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
- Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- Over Half of RA Patients Remained in Remission 1 Year After Stopping Enbrel: Prof. Yamanaka
March 11, 2015
- Alogliptin Demonstrates No Increased Risk of Heart Failure: Takeda
March 11, 2015
- University of Tokyo, Sanofi Collaborate for Joint Drug Discovery Research in Fields of Inflammatory Disease, Oncology
March 11, 2015
- Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
March 10, 2015
- Astellas Wins US Approval for Antifungal Agent Cresemba
March 10, 2015
- Ethical Drug Sales Down 0.1% in January: Crecon Report
March 10, 2015
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
- Meiji Seika Pharma Commences PIII Study of Ziprasidone in Japan
March 9, 2015
- RaQualia, Nagoya Univ. Enter Joint Research Agreement for DNA Polymerase Eta Inhibitors
March 9, 2015
- US Merck, Eisai to Jointly Develop Combination Therapy of Anti-PD-1 Therapy with Anticancer Agents in US
March 9, 2015
- Eisai Aims at 120 Billion Yen Sales for Lenvima: CEO Naito
March 6, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…